Online citations, reference lists, and bibliographies.
← Back to Search

Piroxicam Solid State Studies After Processing With SAS Technique

N. D. Zordi, I. Kikic, M. Moneghini, D. Solinas
Published 2010 · Chemistry

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Abstract Supercritical carbon dioxide (SCO 2 ) was used as anti-solvent to precipitate Piroxicam, a nonsteroidal anti-inflammatory drug, from different organic solvents (acetone, ethyl acetate and dichloromethane). Physicochemical properties of the samples were analyzed before and after the treatment to highlight possible changes in the form of the crystals. The solid state analysis of both products untreated and treated with CO 2 , showed that the applied method choose a particle size reduction and transition to the pure α form resulting in needle-shaped crystals, regardless of the chosen solvent. In order to identify which process was responsible for the above results, Piroxicam was further precipitated from the same three solvents by traditional evaporation method (RV-samples). The dissolution profiles of Piroxicam processed in SCO 2 show a better dissolution performance of Piroxicam over their corresponding system obtained by traditional evaporation method. These results manifest that SAS technology is a controllable way to improve bioavailability of water-insoluble drugs.
This paper references
10.1002/JPS.10186
Physicochemical characterization of solid dispersions of carbamazepine formulated by supercritical carbon dioxide and conventional solvent evaporation method.
S. Sethia (2002)
10.1023/A:1020477204512
Supercritical Fluids Crystallization of Budesonide and Flunisolide
S. Velaga (2004)
10.2174/187221208783478561
Precipitation Processes with Supercritical Fluids: Patents Review
M. J. Mart'in (2008)
10.1023/A:1011000915769
Characterization of Two Polymorphs of Salmeterol Xinafoate Crystallized From Supercritical Fluids
H. Tong (2004)
Polymorphism in Pharmaceutical Solids
H. Brittain (1999)
10.1021/JA045823T
Mechanochromism of piroxicam accompanied by intermolecular proton transfer probed by spectroscopic methods and solid-phase changes.
A. Sheth (2005)
10.1021/OP990160Z
Control of the Physical Form of Salmeterol Xinafoate
Steve Beach (1999)
10.1063/1.3060771
Properties of Gases and Liquids
R. Reid (1977)
10.1016/J.SUPFLU.2007.09.016
Ways of manipulating the polymorphism of glycine during supercritical fluid crystallisation
A. Bouchard (2008)
10.1016/S0896-8446(02)00094-3
Recrystallization of sulfathiazole and chlorpropamide using the supercritical fluid antisolvent process
Sang-Do Yeo (2003)
10.1016/S0896-8446(02)00189-4
DELOS process: a crystallization technique using compressed fluids: 1. Comparison to the GAS crystallization method
N. Ventosa (2003)
10.1021/IE00038A051
Solubility and Micronization of Griseofulvin in Supercritical Chf3
E. Reverchon (1995)
10.1016/J.SUPFLU.2003.09.005
Crystallization of sulfamethizole using the supercritical and liquid antisolvent processes
Sang-Do Yeo (2004)
10.1021/CG049876Y
Polymorphism in Piroxicam
A. Sheth (2004)
10.1016/J.POWTEC.2004.02.007
Particle generation for pharmaceutical applications using supercritical fluid technology
J. Fages (2004)
THEORY AND ORIGIN OF POLYMORPHISM
D. J. Grant (1999)
10.1016/S0378-5173(03)00057-7
Characterization of piroxicam crystal modifications.
F. Vrečer (2003)
10.1016/0378-5173(91)90124-7
Investigation of piroxicam polymorphism
F. Vrecˇer (1991)
10.1002/AIC.690460913
Generation of microparticles using CO2 and CO2‐philic antisolvents
M. Sarkari (2000)
10.1023/A:1016212804288
A Theoretical Basis for a Biopharmaceutic Drug Classification: The Correlation of in Vitro Drug Product Dissolution and in Vivo Bioavailability
G. Amidon (2004)
10.1016/0896-8446(95)90033-0
Volume expansions and vapor-liquid equilibria of binary mixtures of a variety of polar solvents and certain near-critical solvents
A. Kordikowski (1995)
10.1023/A:1011045729706
Polymorph Control of Sulfathiazole in Supercritical CO2
A. Kordikowski (2004)
10.1016/S0896-8446(03)00035-4
Anti-solvent and co-solvent effect of CO2 on the solubility of griseofulvin in acetone and ethanol solutions
B. D. Gioannis (2004)
10.1016/S0939-6411(03)00092-4
Study of the solid state of carbamazepine after processing with gas anti-solvent technique.
M. Moneghini (2003)
10.1021/JE60068A015
Isothermal Vapor-Liquid Equilibrium Data for Binary Systems Containing Carbon Dioxide at High Pressures: Methanol-Carbon Dioxide, n-Hexane-Carbon Dioxide, and Benzene-Carbon Dioxide Systems
K. Ohgaki (1976)
10.1016/S0378-5173(01)00711-6
Processing of carbamazepine-PEG 4000 solid dispersions with supercritical carbon dioxide: preparation, characterisation, and in vitro dissolution.
M. Moneghini (2001)
10.1021/CG900003M
Production of Polymorphs of Ibuprofen Sodium by Supercritical Antisolvent (SAS) Precipitation
Ángel Martín (2009)
10.4155/fmc.09.166
Characterization of solid dispersions of itraconazole and vitamin E TPGS prepared by microwave technology.
M. Moneghini (2010)
10.1016/J.JCRYSGRO.2007.09.010
Solvent effect on tolbutamide crystallization induced by compressed CO2 as antisolvent
P. Subra-Paternault (2007)
10.1016/J.SUPFLU.2005.03.008
A comparison between semi-empirical and molecular-based equations of state for describing the thermodynamic of supercritical micronization processes
Sara Colussi (2006)
10.1021/JE960103Q
Solubility of Anti-Inflammatory Drugs in Supercritical Carbon Dioxide
S. J. Macnaughton (1996)
10.1016/J.SUPFLU.2008.08.015
Encapsulation and co-precipitation processes with supercritical fluids: Fundamentals and applications
M. J. Cocero (2009)
CHARACTERIZATION OF POWDER PARTICLE MORPHOLOGY
V. Mikli (2001)



This paper is referenced by
10.1021/JE200853G
Antisolvent Precipitation of Vitamin B6: A Thermodynamic Study
I. Kikic (2011)
Formation of Cyclodextrin-Drug Inclusion Compounds and Polymeric Drug Delivery Systems using Supercritical Carbon Dioxide
Heather E. Grandelli (2013)
10.1515/revce-2015-0059
Survey of supercritical fluid techniques for producing drug delivery systems for a potential use in cancer therapy
A. Tabernero (2016)
10.1016/J.SUPFLU.2012.07.001
Melting point depression of Piroxicam in carbon dioxide + co-solvent mixtures and inclusion complex formation with β-cyclodextrin
Heather E. Grandelli (2012)
10.1016/J.SUPFLU.2011.09.018
Solubility of pharmaceutical compounds in supercritical carbon dioxide
N. D. Zordi (2012)
10.1016/j.ejps.2012.12.026
Preparation of apigenin nanocrystals using supercritical antisolvent process for dissolution and bioavailability enhancement.
J. Zhang (2013)
10.1016/j.ejpb.2012.01.002
Applications of supercritical fluids to enhance the dissolution behaviors of Furosemide by generation of microparticles and solid dispersions.
Nicola De Zordi (2012)
10.1016/j.ijpharm.2017.12.041
Enhancing the solubility and bioavailability of poorly water-soluble drugs using supercritical antisolvent (SAS) process.
S. M. Abuzar (2018)
10.4155/tde.13.146
Critical gases for critical issues: CO2 technologies for oral drug delivery.
H. Danan (2014)
10.1016/j.ejpb.2014.11.027
Solid state transformations in consequence of electrospraying--a novel polymorphic form of piroxicam.
M. Nyström (2015)
10.1016/j.ijpharm.2012.06.022
Preparation and characterization of 5-fluorouracil-loaded PLLA-PEG/PEG nanoparticles by a novel supercritical CO2 technique.
Cheng Zhang (2012)
olubility of pharmaceutical compounds in supercritical carbon dioxide
De Zordia (2011)
10.1016/J.JCT.2012.02.034
Excess molar enthalpies for mixtures of supercritical CO2 and ethyl acetate and their role in supercritical fluid applications
F. Zahran (2012)
10.1080/07373937.2012.679348
Engineering Active Pharmaceutical Ingredients by Spray Drying: Effects on Physical Properties and In Vitro Dissolution
R. Martins (2012)
Semantic Scholar Logo Some data provided by SemanticScholar